- US stocks retreat while yen gains on Bank of Japan rate hike
- Serbians strike in protest over fatal roof collapse
- Meta plans to invest $60 bn or more in AI this year
- Power cuts and transport chaos as Storm Eowyn hits Ireland and UK
- Croatians boycott shopping to protest high prices
- US home sales in 2024 weakest in nearly 30 years
- 'White wall' of ice drifts toward remote penguin haven
- Stocks diverge as investors weigh earnings, Trump policies
- Beached whales: Airbus grounds its massive Beluga cargo flights
- IMF chief tells Europe to take page out of US book
- Bob Dylan a contrast to 'narcissistic' modern stars, says biopic director
- Saudis showcase charm offensive in Davos
- Maltese businessman accused in journalist's murder granted bail
- Kazakhstan delays release of Azerbaijan plane black box data
- France asks EU to delay rights, environment business rules
- Troubled Burberry shows sign of recovery despite sales drop
- Italy's Monte dei Paschi bids 13.3 bn euros for Mediobanca
- How the Taliban restrict women's lives in Afghanistan
- Bank of Japan hikes interest rate to 17-year high, boosts yen
- Catalonia eyes reversal of business exodus after big bank returns
- Tajikistan launches crackdown on 'witchcraft' and fortune-telling
- Bank of Japan hikes interest rate to 17-year high, signals more
- Asian markets build on Trump rally, yen climbs after BoJ cut
- Survivors strive to ensure young do not forget Auschwitz
- Asian markets build on Trump rally, yen steady ahead of BoJ
- OpenAI unveils 'Operator' agent that handles web tasks
- Bamboo farm gets chopping for US zoo's hungry new pandas
- Fear in US border city as Trump launches immigration overhaul
- 242 mn children's schooling disrupted by climate shocks in 2024: UNICEF
- US Republicans pressure Democrats with 'born-alive' abortion bill
- Trump Davos address lifts S&P 500 to record, dents oil prices
- Between laughs and 'disaster', Trump divides Davos
- Hundreds of people protest ahead of Swiss Davos meeting
- US falling behind on wind power, think tank warns
- US news giant CNN eyes 200 job cuts, streaming overhaul
- Rubio chooses Central America for first trip amid Panama Canal pressure
- Wall Street's AI-fuelled rally falters, oil slumps
- Trump tells Davos elites: produce in US or pay tariffs
- Progressive politics and nepo 'babies': five Oscar takeaways
- American Airlines shares fall on lackluster 2025 profit outlook
- France to introduce new sex education guidelines in schools
- Wall Street's AI-fuelled rally falters
- Drinking water in many French cities contaminated: study
- After Musk gesture, activists project 'Heil' on Tesla plant
- ICC prosecutor seeks arrest of Taliban leaders over persecution of women
- Syria's economy reborn after being freed from Assad
- Shoppers unaware as Roman tower lurks under French supermarket
- Stocks mainly rise after Wall Street's AI-fuelled rally
- Singer Chris Brown sues Warner Bros for $500 mn over documentary
- J-pop star Nakai to retire after sexual misconduct allegations
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
T.Morelli--CPN